Return to homepagePandemic Pact

alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19

  • Funded by Swiss National Science Foundation (SNSF)
  • Total publications:0 publications

Grant number: 54121.1 IP-LS

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2022

  • Known Financial Commitments (USD)

    $377,284.78

  • Funder

    Swiss National Science Foundation (SNSF)

  • Principal Investigator

    Origène Nyanguile

  • Research Location

    Switzerland

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The SARS-CoV2 pandemic is a major health, economic and societal issue worldwide. Despite the advent of vaccines, novel therapeutic and diagnostic options are needed. Here, we wish to use S artificial nanoligands to develop novel potent entry inhibitors and a non-antigenic test for massive screening.